What is the prevalence of Adult T-cell leukemia/lymphoma ATL?

Adult T-cell leukemia/lymphoma (ATL) is a rare, aggressive malignancy of T-lymphocytes caused by the Human T-cell leukemia virus type 1 (HTLV-1). Prevalence is highly concentrated in specific endemic regions, with global estimates of approximately 10 to 20 million people infected with HTLV-1, though only a small fraction (roughly 3–5%) of those individuals will develop Adult T-cell leukemia/lymphoma during their lifetime.

What is the geographic distribution of Adult T-cell leukemia/lymphoma?

The prevalence of Adult T-cell leukemia/lymphoma is not uniform globally. It is considered endemic in Southwest Japan, the Caribbean, parts of Central and South America, sub-Saharan Africa, and Melanesia. In Japan alone, there are estimated to be over 1,000 new cases of Adult T-cell leukemia/lymphoma diagnosed annually. Due to migration, cases are increasingly identified in non-endemic areas, though they remain rare.

Who is most commonly affected by Adult T-cell leukemia/lymphoma?

Adult T-cell leukemia/lymphoma typically presents in middle-aged or older adults, with the median age of onset ranging from 55 to 60 years. While both sexes are affected, some clinical cohorts suggest a slight male predominance. Because Adult T-cell leukemia/lymphoma often has a long latency period—sometimes decades between initial viral infection and cancer development—it is almost exclusively an adult-onset disease.

Why is accurate prevalence data for Adult T-cell leukemia/lymphoma challenging?

Estimating the exact number of people living with Adult T-cell leukemia/lymphoma is difficult due to several factors:

• Underdiagnosis: Many HTLV-1 carriers remain asymptomatic and may never be screened, leading to undiagnosed cases.


• Misdiagnosis: Because Adult T-cell leukemia/lymphoma can mimic other lymphomas, it is sometimes misclassified without specialized immunophenotyping.


• Data Fragmentation: Rare disease registries, including the DiseaseMaps.org community where 2 members have shared their experiences, provide vital real-world insights, but global surveillance remains inconsistent.

Next steps

• Consult a hematologist-oncologist specializing in T-cell malignancies for diagnostic confirmation.


• Request HTLV-1 serological testing if you reside in or have traveled from an endemic region.


• Connect with the DiseaseMaps.org community to share experiences and learn from other patients navigating Adult T-cell leukemia/lymphoma.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Adult T-cell leukemia/lymphoma (ORPHA:520)


• OMIM (Online Mendelian Inheritance in Man) database


• The International Retrovirology Association (HTLV-1 clinical guidelines)